NYSE:EVHEvolent Health Stock Price, Forecast & News

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVH shares have increased by 17.5% and is now trading at $8.13. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolent Health.

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Evolent Health.

Evolent Health Inc (NYSE:EVH) released its earnings results on Thursday, May, 7th. The technology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The technology company earned $247.29 million during the quarter, compared to analyst estimates of $239.35 million. Evolent Health had a negative net margin of 37.17% and a negative return on equity of 5.78%. View Evolent Health's earnings history.

Evolent Health updated its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $236-247 million, compared to the consensus revenue estimate of $240.29 million.

9 analysts have issued twelve-month target prices for Evolent Health's stock. Their forecasts range from $10.00 to $19.00. On average, they anticipate Evolent Health's share price to reach $14.91 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price. View analysts' price targets for Evolent Health.

Press coverage about EVH stock has trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolent Health earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEvolent Health.

Some companies that are related to Evolent Health include R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Energy Transfer LP Unit (ET), Netflix (NFLX), Micron Technology (MU), Advanced Micro Devices (AMD) and Aegean Marine Petroleum Network (ANW).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (7.66%), BlackRock Inc. (6.71%), Eagle Asset Management Inc. (3.70%), Riverbridge Partners LLC (3.01%), Carillon Tower Advisers Inc. (2.94%) and Bank of New York Mellon Corp (2.33%). Company insiders that own Evolent Health stock include Cheryl Scott, Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley, Thomas Peterson III and Unitedhealth Group Inc. View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Silvercrest Asset Management Group LLC, Riverbridge Partners LLC, Carillon Tower Advisers Inc., Eagle Asset Management Inc., Granahan Investment Management Inc. MA, and Pictet Asset Management Ltd.. View insider buying and selling activity for Evolent Health.

EVH stock was bought by a variety of institutional investors in the last quarter, including DC Investments Management LLC, Bank of New York Mellon Corp, State Street Corp, Rock Point Advisors LLC, JPMorgan Chase & Co., King Luther Capital Management Corp, Profit Investment Management LLC, and Two Sigma Advisers LP. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley. View insider buying and selling activity for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $8.13.

Evolent Health has a market capitalization of $688.77 million and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.